V.A.C.ULTA™ NEGATIVE PRESSURE WOUND THERAPY SYSTEM (V.A.C.ULTA™ THERAPY SYSTEM) SAFETY INFORMATION

Only for use with the KCI V.A.C.Ulta™ Therapy System



TABLE OF CONTENTS

Indications for Use	2
Transitioning V.A.C.® Therapy Into Home Care	
V.A.C.Ulta TM Therapy System Contraindications	
Additional Contraindications specific to V.A.C. VeraFlo™ Therapy	
V.A.C.Ulta™ Therapy System Warnings	
Additional Warnings for V.A.C. VeraFlo™ Therapy	
V.A.C.Ulta™ Therapy System Precautions	
Additional Precautions for V.A.C. VeraFlo™ Therapy	
Additional Precautions for V.A.C. GranuFoam Silver® Dressing:	
Explanation of Symbols Used in Disposables Labeling	13

The V.A.C.Ulta™ Negative Pressure Wound Therapy System (V.A.C.Ulta™ Therapy System) is an integrated wound therapy system that can deliver either:



V.A.C. VeraFlo™ Therapy (Instillation), which consists of negative pressure wound therapy (V.A.C.® Therapy) coupled with controlled delivery and drainage of topical wound irrigation, treatment solutions and suspensions over the wound bed.

OR

• V.A.C.® Therapy, which consists of negative pressure wound therapy alone.



When using V.A.C. VeraFlo™ Therapy (Instillation), there are important

Contraindications, Warnings, and Precautions that should be considered in addition to the Contraindications, Warnings, and Precautions for V.A.C.®

Therapy. Contraindications, Warnings, and Precautions specific to V.A.C.

VeraFlo™ Therapy are highlighted in grey throughout the document and are identified by the V.A.C. VeraFlo™ Therapy symbol to the left of the text. When using V.A.C.® Therapy alone, the V.A.C. VeraFlo™ Therapy Contraindications, Warnings, and Precautions are not applicable.

The V.A.C.Ulta™ Therapy Unit is for use only with V.A.C.® Dressings (V.A.C.® GranuFoam™, V.A.C. GranuFoam Silver®, V.A.C.® WhiteFoam, V.A.C. VeraFlo™ Dressing Systems) and disposables. V.A.C. VeraFlo™ Therapy should only be delivered with V.A.C. VeraFlo™ Dressings and disposables.



NOTE: The V.A.C. GranuFoam Silver® Dressing is not intended to be used with V.A.C. VeraFlo™ Therapy because instillation solutions may negatively impact the benefits of the V.A.C. GranuFoam Silver® Dressing.

IMPORTANT: As with any prescription medical device, failure to consult a physician and carefully read and follow all therapy unit and dressing instructions and safety information prior to each use may lead to improper product performance and the potential for serious or fatal injury. Do not adjust therapy unit settings or perform therapy application without directions from/or supervision by the clinical caregiver.

INDICATIONS FOR USE

The V.A.C.UltaTM Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option.

Negative Pressure Wound Therapy in the absense of instillation is intended to create an environment that promotes wound healing by secondary or tertiary (delayed primary) intention by preparing the wound bed for closure, reducing edema, promoting granulation tissue formation and perfusion, and by removing exudate and infectious material. The instillation option is indicated for patients who would benefit from vacuum assisted drainage and controlled delivery of topical wound treatment solutions and suspensions over the wound bed.

The V.A.C.Ulta™ Negative Pressure Wound Therapy System with and without instillation is indicated for patients with chronic, acute, traumatic, sub-acute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure and venous insufficiency), flaps and grafts.

TRANSITIONING V.A.C.® THERAPY INTO HOME CARE

The V.A.C.Ulta™ Therapy System is not intended for home use. If there is a need to continue V.A.C.® Therapy when a patient transitions home, consider using other KCI Therapy Systems approved for the post-acute care environment. Refer to the safety information included with those devices for important information.

V.A.C.ULTA™ THERAPY SYSTEM CONTRAINDICATIONS

Do not place foam dressings of the V.A.C.Ulta™ Therapy System (including both V.A.C.®
 Therapy and V.A.C. VeraFlo™ Therapy Dressings) directly in contact with exposed blood
 vessels, anastomotic sites, organs, or nerves.

NOTE: Refer to Warnings section for additional information concerning Bleeding.

- V.A.C.® Therapy and V.A.C. VeraFlo™ Therapy are contraindicated for patients with:
 - · Malignancy in the wound
 - Untreated osteomyelitis

NOTE: Refer to Warnings section for Osteomyelitis information.

- · Non-enteric and unexplored fistulas
- Necrotic tissue with eschar present

NOTE: After debridement of necrotic tissue and complete removal of eschar, V.A.C.® Therapy may be used.

• Sensitivity to silver (V.A.C. GranuFoam Silver® Dressing only)

ADDITIONAL CONTRAINDICATIONS SPECIFIC TO V.A.C. VERAFLO™ THERAPY



- Do not use V.A.C.® Dressings with Octenisept®*, hydrogen peroxide or solutions that are alcohol-based or contain alcohol.
- Do not deliver fluids to the thoracic or abdominal cavity due to the potential risk to alter core body temperature and the potential for fluid retention within the cavity.
- Do not use V.A.C. VeraFloTM Therapy unless the wound has been throughly
 explored due to the potential for inadvertent instillation of topical wound
 solutions to adjacent body cavities.
- * Not available in the United States. Brand name referenced is not a trademark of KCI, its affiliates, or licensors.

V.A.C.ULTA™ THERAPY SYSTEM WARNINGS

<u>Bleeding:</u> With or without using V.A.C.® Therapy or V.A.C. VeraFlo™ Therapy, certain patients are at high risk of bleeding complications. The following types of patients are at increased risk of bleeding, which, if uncontrolled, could be potentially fatal.

- Patients who have weakened or friable blood vessels or organs in or around the wound as a result of, but not limited to:
 - Suturing of the blood vessel (native anastamoses or grafts)/organ
 - Infection
 - Trauma
 - Radiation
- Patients without adequate wound hemostasis
- Patients who have been administered anticoagulants or platelet aggregation inhibitors
- Patients who do not have adequate tissue coverage over vascular structures.

If V.A.C.® Therapy or V.A.C. VeraFlo™ Therapy is prescribed for patients who have an increased risk of bleeding complications, they should be treated and monitored in a care setting deemed appropriate by the treating physician.

If active bleeding develops suddenly or in large amounts during V.A.C.® Therapy or V.A.C. VeraFlo™ Therapy, or if frank (bright red) blood is seen in the tubing or in the canister, immediately stop therapy, leave dressing in place, take measures to stop the bleeding, and seek immediate medical assistance. The V.A.C.Ulta™ Therapy Unit and dressings (both V.A.C.® Therapy and V.A.C. VeraFlo™ Therapy) should not be used to prevent, minimize or stop vascular bleeding.

 Protect Vessels and Organs: All exposed or superficial vessels and organs in or around the wound must be completely covered and protected prior to the administration of V.A.C.® Therapy or V.A.C. VeraFloTM Therapy.

Always ensure that V.A.C.® Foam Dressings and V.A.C. VeraFlo™ Foam Dressings do not come in direct contact with vessels or organs. Use of a thick layer of natural tissue should provide the most effective protection. If a thick layer of natural tissue is not available or is not surgically possible, multiple layers of fine-meshed, non-adherent material may be considered as an alternative, if deemed by the treating physician to provide a complete protective barrier. If using non-adherent materials, ensure that they are secured in a manner as to maintain their protective position throughout therapy.

Consideration should also be given to the negative pressure setting and therapy mode used when initiating therapy.

Caution should be taken when treating large wounds that may contain hidden vessels, which may not be readily apparent. The patient should be closely monitored for bleeding in a care setting deemed appropriate by the treating physician.

- Infected Blood Vessels: Infection may erode blood vessels and weaken the vascular wall which may increase susceptibility to vessel damage through abrasion or manipulation. Infected blood vessels are at risk of complications, including bleeding, which, if uncontrolled, could be potentially fatal. Extreme caution should be used when V.A.C.® Therapy or V.A.C. VeraFlo™ Therapy is applied in close proximity to infected or potentially infected blood vessels. (Refer to Protect Vessels and Organs section above.)
- Hemostasis, Anticoagulants, and Platelet Aggregation Inhibitors: Patients without
 adequate wound hemostasis have an increased risk of bleeding, which, if uncontrolled,
 could be potentially fatal. These patients should be treated and monitored in a care
 setting deemed appropriate by the treating physician.
 - Caution should be used in treating patients on doses of anticoagulants or platelet aggregation inhibitors thought to increase their risk for bleeding (relative to the type and complexity of the wound). Consideration should be given to the negative pressure setting and therapy mode used when initiating therapy.
- Hemostatic Agents Applied at the Wound Site: Non-sutured hemostatic agents
 (for example, bone wax, absorbable gelatin sponge, or spray wound sealant) may, if
 disrupted, increase the risk of bleeding, which, if uncontrolled, could be potentially fatal.
 Protect against dislodging such agents. Consideration should be given to the negative
 pressure setting and therapy mode used when initiating therapy. (Refer to Additional
 Warnings for V.A.C. VeraFloTM Therapy section)
- Sharp Edges: Bone fragments or sharp edges could puncture protective barriers, vessels, or organs causing injury. Any injury could cause bleeding, which, if uncontrolled, could be potentially fatal. Beware of possible shifting in the relative position of tissues, vessels or organs within the wound that might increase the possibility of contact with sharp edges. Sharp edges or bone fragments must be eliminated from the wound area or covered to prevent them from puncturing blood vessels or organs before the application of V.A.C.® Therapy or V.A.C. VeraFlo™ Therapy. Where possible, completely smooth and cover any residual edges to decrease the risk of serious or fatal injury, should shifting of structures occur. Use caution when removing dressing components from the wound so that wound tissue is not damaged by unprotected sharp edges.

1000 mL Canister: DO NOT USE the 1000 mL canister on patients with a high risk of bleeding or on patients unable to tolerate a large loss of fluid volume, including children and the elderly. Consider the size and weight of the patient, patient condition, wound type, monitoring capability and care setting when using this canister. This canister is recommended for acute care (hospital) use only.

Infected Wounds: Infected wounds should be monitored closely and may require more frequent dressing changes than non-infected wounds, dependent upon factors such as wound conditions, treatment goals, and V.A.C. VeraFlo™ Therapy parameters (for the V.A.C.Ulta™ Therapy System). Refer to dressing application instructions (found in V.A.C.® Dressing and V.A.C. VeraFlo™ Dressing cartons) for details regarding dressing change frequency. As with any wound treatment, clinicians and patients/caregivers should frequently monitor the patient's wound, periwound tissue and exudate for signs of infection, worsening infection, or other complications. Some signs of infection are fever, tenderness, redness, swelling, itching, rash, increased warmth in the wound or periwound area, purulent discharge, or strong odor. Infection can be serious, and can lead to complications such as pain, discomfort, fever, gangrene, toxic shock, septic shock and/ or fatal injury. Some signs or complications of systemic infection are nausea, vomiting, diarrhea, headache, dizziness, fainting, sore throat with swelling of the mucus membranes, disorientation, high fever, refractory and/orthostatic hypotension, or erythroderma (a sunburn-like rash). If there are any signs of the onset of systemic infection or advancing infection at the wound site, contact a physician immediately to determine if V.A.C.® Therapy or V.A.C. VeraFlo™ Therapy should be discontinued. For wound infections relating to blood vessels, please also refer to the section titled Infected Blood Vessels.

Infected Wounds with V.A.C. GranuFoam Silver® Dressing: In the event of clinical infection, V.A.C. GranuFoam Silver® Dressing is not intended to replace the use of systemic therapy or other infection treatment regimens. V.A.C. GranuFoam Silver® Dressing may be used on infected wounds as an adjunct to the standard treatment regimen and to provide a barrier to bacterial penetration. V.A.C. GranuFoam Silver® should not be used with V.A.C. VeraFloTM Therapy (refer to page 2)

Osteomyelitis: V.A.C.® Therapy and V.A.C. VeraFlo™ Therapy should NOT be initiated on a wound with untreated osteomyelitis. Consideration should be given to thorough debridement of all necrotic, non-viable tissue, including infected bone (if necessary), and appropriate antibiotic therapy.

<u>Protect Tendons, Ligaments and Nerves:</u> Tendons, ligaments and nerves should be protected to avoid direct contact with V.A.C.® Foam Dressings or V.A.C. VeraFlo™ Therapy Foam Dressings. These structures may be covered with natural tissue, or meshed non-adherent material to help minimize risk of desiccation or injury.

Foam Placement: Always use V.A.C.® Dressings or V.A.C. VeraFlo™ Therapy Dressings from sterile packages that have not been opened or damaged. Do not place any foam dressing into blind/unexplored tunnels. The V.A.C.® WhiteFoam Dressing may be more appropriate for use with explored tunnels. Do not force foam dressings into any area of the wound, as this may damage tissue, alter the delivery of negative pressure, or hinder exudate and foam removal. Always count the total number of pieces of foam used in the wound and the dressing change date and document that number on the drape, in the patient's chart and, if provided, on the foam quantity label attached to the pad tubing.

Foam Removal: V.A.C.® Foam Dressings and V.A.C. VeraFlo™ Therapy Foam Dressings are not bioabsorbable. Always count the total number of pieces of foam removed from the wound and ensure the same number of foam pieces was removed as placed. Foam left in the wound for greater than the recommended time period may foster ingrowth of tissue into the foam, create difficulty in removing foam from the wound, or lead to infection or other adverse events. If significant bleeding develops, immediately discontinue the use of the V.A.C.Ulta™ Therapy System, take measures to stop the bleeding, and do not remove the oam dressing until the treating physician or surgeon is consulted. Do not resume the use of the V.A.C.® Therapy or V.A.C. VeraFlo™ Therapy until adequate hemostasis has been achieved, and the patient is not at risk for continued bleeding.

Keep V.A.C.® Therapy and V.A.C. VeraFlo™ Therapy On: Never leave a V.A.C.® Dressing or V.A.C. VeraFlo™ Therapy Dressing in place without active V.A.C.® Therapy or V.A.C. VeraFlo™ Therapy for more than 2 hours. If therapy is off for more than 2 hours, remove the old dressing and irrigate the wound. Either apply a new V.A.C.® Dressing or V.A.C. VeraFlo™ Therapy Dressing from an unopened sterile package and restart therapy; or apply an alternative dressing at the direction of the treating clinician.

Acrylic Adhesive: The V.A.C.® Drape (supplied with V.A.C.® Dressings and V.A.C. VeraFlo™ Therapy Dressings) has an acrylic adhesive coating, which may present a risk of an adverse reaction in patients who are allergic or hypersensitive to acrylic adhesives. If a patient has a known allergy or hypersensitivity to such adhesives, do not use the V.A.C.Ulta™ Therapy System. If any signs of allergic reaction or hypersensitivity develop, such as redness, swelling, rash, urticaria, or significant pruritus, discontinue use and consult a physician immediately. If bronchospasm or more serious signs of allergic reaction appear, seek immediate medical assistance.

<u>**Defibrillation:**</u> Remove the V.A.C.® Dressing or V.A.C. VeraFlo[™] Therapy Dressing if defibrillation is required in the area of dressing placement. Failure to remove the dressing may inhibit transmission of electrical energy and/or patient resuscitation.

Magnetic Resonance Imaging (MRI) – Therapy Unit: The V.A.C.Ulta™ Therapy Unit is MR Unsafe. Do not take the V.A.C.Ulta™ Therapy Unit into the MR environment.

Magnetic Resonance Imaging (MRI) – V.A.C.® Dressings: V.A.C.® Dressings and V.A.C. VeraFlo™ Therapy Dressings can typically remain on the patient with minimal risk in an MR environment, assuming that use of the V.A.C.Ulta™ Therapy System is not interrupted for more than 2 hours (refer to Keep V.A.C.® Therapy On above).



NOTE: If using V.A.C. VeraFlo™ Therapy ensure that irrigation fluid or treatment solutions are fully removed from the dressing prior to stopping negative pressure wound therapy.

The V.A.C. GranuFoam Silver® Dressing has been shown to pose no known hazards in an MR environment with the following conditions of use:

- Static magnetic field of 3 Tesla or less,
- Spatial gradient field of 720 Gauss/cm or less, and
- Maximum whole-body-averaged specific absorption rate (SAR) of 3 W/kg for 15 minutes of scanning.

Non-clinical testing under these same conditions produced a temperature rise of <0.4°C. MR image quality may be compromised if the area of interest is in the same area or relatively close to the position of the V.A.C. GranuFoam Silver® dressing.

Hyperbaric Oxygen Therapy (HBO): Do not take the V.A.C.Ulta™ Therapy Unit into a hyperbaric oxygen chamber. The V.A.C.Ulta™ Therapy Unit is not designed for this environment, and should be considered a fire hazard. After disconnecting the V.A.C.Ulta™ Therapy Unit, either (i) replace the V.A.C.® Dressing or V.A.C. VeraFlo™ Therapy Dressing with another HBO compatible material during the hyperbaric treatment, or (ii) cover the unclamped end of the V.A.C.® Tubing with moist cotton gauze and completely cover the V.A.C.® Dressing or V.A.C. VeraFlo™ Therapy Dressing (including tubing) with a moist towel throughout the treatment in the chamber. For HBO therapy, the V.A.C.® Tubing or V.A.C. VeraFlo™ Therapy tubing must not be clamped. Never leave a V.A.C.® Dressing in place without active V.A.C.® Therapy for more than 2 hours; please refer to the Keep V.A.C.® Therapy On section above.



NOTE: If using V.A.C. VeraFlo™ Therapy ensure that irrigation fluid or treatment solutions are fully removed from the dressing prior to stopping negative pressure wound therapy.

ADDITIONAL WARNINGS FOR V.A.C. VERAFLO™ THERAPY



<u>Topical Wound Solutions:</u> Topical wound solutions or suspensions may enter internal body cavities if the wound is open to such cavities. They should not be infused into wounds with unexplored tunnels or unexplored undermining as they may enter into unintended cavities.

Pauses in Negative Pressure: Application of V.A.C. VeraFlo[™] Therapy will result in pauses of negative pressure wound therapy, which is not recommended on wounds requiring continuous V.A.C.® Therapy. Do not use V.A.C. VeraFlo[™] Therapy over unstable structures, such as unstable chest wall or non-intact fascia, on patients at increased risk of bleeding, highly exudating wounds, on flaps, grafts or wounds with acute enteric fistulae.

<u>Bioengineered Tissue:</u> V.A.C. VeraFloTM Therapy is not intended for use with cellular or accellular bioengineered tissues.

Hemostasis: Patients with difficult or fragile wound hemostasis are at increased risk of bleeding associated with V.A.C. VeraFlo™ Therapy due to the potential for disruption of clots or dilution of clotting factors. Do not use V.A.C. VeraFlo™ Therapy where hemostatic agents have been used in the wound bed.

V.A.C.ULTA™ THERAPY SYSTEM PRECAUTIONS

<u>Standard Precautions</u>: To reduce the risk of transmission of bloodborne pathogens, apply standard precautions for infection control with all patients, per institutional protocol, regardless of their diagnosis or presumed infection status. In addition to gloves, use gown and goggles if exposure to body fluids is likely.

Continuous versus DPC (Dynamic Pressure Control) V.A.C.[®] Therapy: Continuous V.A.C.[®] Therapy is recommended over unstable structures, such as an unstable chest wall or non-intact fascia, in order to help minimize movement and stabilize the wound bed. Continuous therapy is also generally recommended for patients at increased risk of bleeding, highly exudating wounds, fresh flaps and grafts, and wounds with acute enteric fistulae.



NOTE: V.A.C. VeraFlo™ Therapy, due to the controlled delivery of wound irrigation and treatment solutions, provides intermittent V.A.C.® Therapy and is not recommended in the above wound types or conditions.

Patient Size and Weight: The size and weight of the patient should be considered when prescribing V.A.C.® Therapy or V.A.C. VeraFlo™ Therapy. Infants, children, certain small adults and elderly patients should be closely monitored for fluid loss and dehydration. Also, patients with highly exudating wounds or large wounds in relation to the patient size and weight should be closely monitored, as they have a risk of excessive fluid loss and dehydration. When monitoring fluid output, consider the volume of fluid in both the tubing and canister.

Spinal Cord Injury (SCI): In the event an SCI patient experiences autonomic dysreflexia (sudden changes in blood pressure or heart rate in response to stimulation of the sympathetic nervous system), discontinue V.A.C.

Priority Therapy to help minimize sensory stimulation and seek immediate medical assistance.**

<u>Bradycardia:</u> To minimize the risk of bradycardia, V.A.C.® Therapy and V.A.C. VeraFlo™ Therapy must not be placed in proximity to the vagus nerve.

<u>Enteric Fistulas:</u> Wounds with enteric fistulas require special precautions to optimize V.A.C.® Therapy. Refer to V.A.C.® Therapy Clinical Guidelines for more detail. V.A.C.® Therapy is not recommended if enteric fistula effluent management or containment is the sole goal of therapy.



NOTE: V.A.C. VeraFloTM Therapy should not be used in the presence of enteric fistula to prevent wound contamination.

Protect Periwound Skin: Consider use of a skin preparation product to protect periwound skin. Do not allow foam to overlap onto intact skin. Protect fragile/friable periwound skin with additional V.A.C.® Drape, skin protectant, hydrocolloid, or other transparent film. Multiple layers of the V.A.C.® Drape may decrease the moisture vapor transmission rate, which may increase the risk of maceration. If any signs of irritation or sensitivity to the drape, foam, or tubing assembly appear, discontinue use and consult a physician. To avoid trauma to the periwound skin, do not pull or stretch the drape over the foam dressing during drape application. Extra caution should be used for patients with neuropathic etiologies or circulatory compromise.

Circumferential Dressing Application: Avoid use of circumferential dressings except in the presence of anasarca or excessively weeping extremities, where a circumferential drape technique may be necessary to establish and maintain a seal. Consider using multiple small pieces of V.A.C.® Drape rather than one continuous piece to minimize the risk of decreased distal circulation. Extreme care should be taken not to stretch or pull the drape when securing it, but let it attach loosely and stabilize the edges with an elastic wrap, if necessary. When using circumferential drape applications, it is crucial to systematically and recurrently palpate distal pulses, and assess distal circulatory status. If circulatory compromise is suspected, discontinue therapy, remove dressing, and contact a physician.

<u>Pressure Points:</u> Periodically assess and monitor the location of tubing connectors, caps, clamps or other rigid components to ensure they do not create inadvertent pressure points in relation to patient position.

<u>V.A.C.Ulta™ Therapy Unit Pressure Excursions</u>: In rare instances, tubing blockages with the V.A.C.Ulta™ Therapy Unit may result in brief vacuum excursions to more than 250 mmHg negative pressure. Resolve alarm conditions immediately. Refer to the V.A.C.Ulta™ Therapy System User Manual or contact your KCI Clinical Account Manager for additional information.

ADDITIONAL PRECAUTIONS FOR V.A.C. VERAFLO™ THERAPY



<u>Suitable Solutions:</u> V.A.C. VeraFlo[™] Therapy is intended for use with V.A.C. VeraFlo[™] Therapy disposables and topical wound treatment solutions and suspensions. Only use solutions or suspensions that are:

- Indicated for topical wound treatment according to solution manufacturer's
 instructions for use. Some topical agents may not be intended for extended
 tissue contact. If in doubt about the appropriateness of using a particular
 solution for V.A.C. VeraFlo™ Therapy, contact the solution's manufacturer
 about its suitability for saturated topical wound exposure.
- Compatible with V.A.C.® Dressings and disposable components. Contact your KCI Clinical Account Manager for a list of solutions shown to be compatible with V.A.C.® Dressings and disposable components.

NOTE: Hypochlorous acid solutions applied frequently at high concentrations can lead to significant material degradation. Consider utilizing concentrations and exposure durations as low as clinically relevant.

NOTE: The V.A.C. GranuFoam Silver® Dressing is not intended to be used with V.A.C. VeraFlo™ Therapy because instillation solutions may negatively impact the benefits of the V.A.C. GranuFoam Silver® Dressing.

Canister Changes: Monitor fluid level in canisters frequently during use of the V.A.C. VeraFlo™ Therapy. Frequent canister changes may be necessary depending on volume of fluid instilled and wound exudates. At a minimum the canister should be changed weekly and disposed of according to institutional protocol.

ADDITIONAL PRECAUTIONS FOR V.A.C. GRANUFOAM SILVER® DRESSING:



<u>Topical Solutions or Agents:</u> The V.A.C. GranuFoam Silver® Dressing is not intended to be used with V.A.C. VeraFlo[™] Therapy because instillation solutions may negatively impact the benefits of the V.A.C. GranuFoam Silver® Dressing.

Protective Layer: For maximum effectiveness, the V.A.C. GranuFoam Silver® Dressing should be applied directly to the wound surface to enhance optimal contact of the tissue with the foam/ silver interface. However, as with all V.A.C.® Foam Dressings, the V.A.C. GranuFoam Silver® Dressing should not be placed in direct contact with exposed blood vessels, anastomotic sites, organs, or nerves (refer to section on Protect Vessels and Organs). Intervening non-adherent layers may be placed between the V.A.C. GranuFoam Silver® Dressing and the wound surface; however, these products may compromise the effectiveness of the V.A.C. GranuFoam Silver® Dressing in the area covered by the non-adherent layer.

<u>Electrodes or Conductive Gel:</u> Do not allow V.A.C. GranuFoam Silver® Dressing to come in contact with EKG or other electrodes or conductive gels during electronic monitoring or when taking electronic measurements.

<u>Diagnostic Imaging</u>: The V.A.C. GranuFoam Silver® Dressing contains metallic silver that may impair visualization with certain imaging modalities.

<u>Dressing Components:</u> The V.A.C. GranuFoam Silver® Dressing contains elemental silver (10%) as a sustained release formulation. Application of products containing silver may cause temporary tissue discoloration.

Additional warnings and precautions apply to certain V.A.C.® specialty dressings and V.A.C.® Therapy Units. Please refer to the specific product Instructions for Use prior to use.

If there are any questions regarding the proper placement or usage of V.A.C.® Therapy, please refer to the V.A.C.® Therapy Clinical Guidelines for more detailed instructions, or contact your local KCI Clinical Account Manager. For additional and most current information, please see KCI's website at www.kci1.com.

EXPLANATION OF SYMBOLS USED IN DISPOSABLES LABELING

Method of Sterilization -STERILE R Keep Dry Radiation Do not use if package is damaged or open **Expiration Date** Latex Free Date of Manufacture Single Use Only Do Not Resterilize

Lot/Batch Number

Consult Instructions for Use

Manufacturer

Rx Only

Resterilize

CAUTION: Federal (US) law restricts this device to sale/rental by or on the order of a physician



Authorized Representative in the European Community



Contains PHTHALATES (V.A.C. VeraT.R.A.C.™ Pad tubing, V.A.C. VeraT.R.A.C. Duo™ Tube Set tubing, V.A.C. VeraLink™ Cassette tubing)



Always count and record number of foam pieces used in wound.





KCI Wedical Produc San Antonio, TX 78219 USA Wimborne, Dorset 1-800-275-4524 BH21 75H www.kci1.com United Kingdom

EC REP

KCI Medical Products (UK), Ltd. Wimborne, Dorset BH21 7SH United Kingdom www.kci-medical.com

3M™ Tegaderm™ and Cavilon™ are trademarks of 3M™ Corporation. Unless otherwise specifically noted in the text, all other trademarks designated herein are proprietary to KCI Licensing, Inc., its affiliates and licensors. ©2010 KCI Licensing, Inc. All rights reserved.